Welcome to our dedicated page for Autonomix Medical SEC filings (Ticker: AMIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Autonomix Medical, Inc. filings document a development-stage medical device company focused on precision nerve-targeted technology and transvascular approaches to peripheral nerve sensing and treatment. Securities registration statements describe the company’s common stock, warrant instruments, offering mechanics, emerging growth company status, smaller reporting company status, financial statements, convertible note proceeds, and related-party transaction disclosures.
Autonomix’s 8-K filings cover material events including Regulation FD clinical-data disclosures, private placement financing agreements involving pre-funded warrants and Series C warrants, annual meeting voting results, board and auditor matters, reverse stock split authority, and Nasdaq continued-listing compliance notices. These records also reflect capital-structure changes and governance actions tied to the company’s public-company status.
Autonomix Medical, Inc. reported that as of July 28, 2026, its cash balance was approximately $5.1 million and it had 971,043 shares of common stock outstanding.
The outstanding share count includes common shares issued in connection with a warrant inducement dated July 13, 2026, providing an updated snapshot of the company’s cash position and capital structure.
Autonomix Medical, Inc. entered into a warrant inducement arrangement with an existing investor covering Series C/November 2025 warrants to purchase 428,731 shares of common stock. The company reduced the exercise price on these registered warrants to $6.00 per share, and the investor agreed to exercise them for anticipated gross proceeds of about $2.6 million, before fees and expenses.
In return, Autonomix will issue the investor two new unregistered warrant series, D-1 and D-2, each exercisable for up to 428,731 shares at $5.75 per share, with a 5.5-year term and beneficial ownership caps of 4.99% or 9.99%. The company committed to file, within 15 days, a resale registration statement for the shares underlying these new warrants and to seek effectiveness within 45 to 75 days, while paying Maxim Group LLC a 7.0% cash fee on warrant-exercise proceeds plus up to $15,000 of expenses.
Autonomix Medical, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for listing on the Nasdaq Capital Market. The company had previously received a Nasdaq deficiency notice on January 14, 2026 after its common stock closed below $1.00 per share for 30 consecutive business days. Nasdaq informed Autonomix on July 9, 2026 that the closing bid price was at or above $1.00 per share for 10 consecutive business days from June 24, 2026 through July 8, 2026, restoring compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq has indicated the matter is closed.
Autonomix Medical, Inc. is implementing a 1-for-21 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on June 24, 2026. The shares will continue trading on the Nasdaq Capital Market under the symbol AMIX with a new CUSIP 05330T304.
Every 21 issued and outstanding common shares will be combined into one share, with the par value remaining $0.001. The number of common shares outstanding will be reduced from 11,409,344 to approximately 542,000, while authorized common shares will remain at 500 million.
Proportionate adjustments will be made to outstanding stock options, warrants and equity plan reserves. No fractional shares will be issued; instead, holders entitled to a fraction will receive cash based on the average closing price over the five trading days preceding the split.
The company also provided illustrative financial data, showing that for the year ended March 31, 2026, net loss was $16.7 million and net loss per common share – basic and diluted – adjusts from $2.32 pre-split to $48.80 post-split after applying the reverse split ratio.
Autonomix Medical, Inc. files an amendment to its annual report to add detailed Part III information on directors, executive compensation, ownership, related-party oversight, and auditor fees. The company reports aggregate market value of non‑affiliate voting equity of $6,307,279 and 11,409,344 shares outstanding as of June 10, 2026.
For fiscal 2026, CEO Brad Hauser received total compensation of $670,176, while Vice Chair Lori Bisson and CFO Trent Smith received $204,000 and $381,763, respectively. The filing describes board committee structures, independence determinations, anti‑hedging and insider trading policies, a Dodd‑Frank–style recoupment policy, and outlines equity plans and option cancellations that left named executive officers and non‑employee directors with no outstanding equity awards as of March 31, 2026.
Autonomix Medical, Inc. is a development-stage medical device company building a catheter-based system that can sense tiny peripheral nerve signals and deliver targeted radiofrequency ablation, aiming for a “sense, treat, verify” workflow initially focused on pancreatic cancer pain.
The company sees large potential markets across pain management, hypertension and other nerve-related disorders, but currently has no approved products or product revenue and depends on third-party manufacturers. It plans a De Novo FDA pathway, with U.S. IDE trials anticipated to start in late 2026 using its proprietary sensing and ablation catheters.
As of March 31, 2026, Autonomix had an accumulated deficit of $67.1 million, negative operating cash flow of $12.3 million, and working capital of $5.9 million, which raises substantial doubt about its ability to continue as a going concern without new financing. Management believes existing capital lasts into the fourth calendar quarter of 2026 and highlights significant regulatory, clinical, manufacturing, cybersecurity and Nasdaq listing risks.
Autonomix Medical, Inc. reported another quarter as a pre-revenue, clinical-stage medical device company, advancing a catheter-based platform that combines nerve signal sensing with RF ablation to treat peripheral nervous system disorders, initially focused on pancreatic cancer pain and other visceral cancers.
For the nine months ended December 31, 2025, the company recorded a net loss of $14.0 million, up from $8.2 million a year earlier, driven by higher research and development spending of $5.7 million and general and administrative costs of $8.6 million. Cash used in operating activities was $9.4 million, leaving cash of $9.9 million and working capital of $8.5 million at period end.
Autonomix strengthened its balance sheet through equity financing, including at-the-market issuances, a Lincoln Park equity line, warrant inducement transactions and a November 2025 private placement that generated about $5.0 million in gross proceeds. However, the company had an accumulated deficit of $64.4 million and disclosed substantial doubt about its ability to continue as a going concern, estimating its current cash will fund operations into but not beyond the third calendar quarter of 2026 and that approximately $30–$36 million of additional financing will be needed to reach commercialization of its first indication.
Autonomix Medical, Inc. received a notice from Nasdaq that its common stock has failed to meet the minimum $1.00 per share bid price requirement for the last 30 consecutive business days, triggering a deficiency under Nasdaq’s continued listing rules.
The company has an initial 180-day grace period until July 13, 2026 to regain compliance by having its closing bid price at or above $1.00 for at least 10 consecutive business days. If it still falls short, Autonomix may qualify for a second 180-day period if it meets other Nasdaq Capital Market listing standards.
If compliance is not restored and no additional period is granted, Autonomix’s common stock may be delisted from Nasdaq, although the company could appeal. Management is monitoring the share price and may consider options such as a reverse stock split, but there is no assurance it will regain compliance.
Autonomix Medical, Inc. furnished an update highlighting new subgroup clinical data from its proof-of-concept study in pancreatic cancer-related pain. The analysis, presented at the 2026 ASCO Gastrointestinal Cancers Symposium, is described as demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages, expanding on previously reported results from the ongoing evaluation.
The company also posted an updated corporate presentation on its website, which is included as an exhibit. Both the press release and the investor presentation are furnished under a Regulation FD disclosure and are not deemed filed under federal securities laws unless later specifically incorporated by reference.
Autonomix Medical, Inc. has filed a prospectus covering the resale of up to 13,504,998 shares of common stock issuable upon exercise of outstanding warrants issued in a November 2025 PIPE transaction. This includes 9,003,332 shares underlying Series C common stock purchase warrants and 4,501,666 shares underlying pre-funded warrants. The company will not receive any proceeds from share resales by the selling stockholder but could receive up to $7.7 million in gross proceeds if all Common Warrants are exercised in cash, which it plans to use for working capital and general corporate purposes.
The warrants are immediately exercisable, with Common Warrants priced at $0.8607 per share and expiring five and a half years after issuance, and Pre-Funded Warrants priced at $0.001 per share and expiring when fully exercised. Shares outstanding were 6,907,678 as of November 21, 2025. The filing highlights that registering a large number of resale shares could pressure the stock price and materially dilute existing holders, and notes an auditor going concern paragraph regarding the company’s ability to continue as a going concern.